Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:2005
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
ongoing studies |
| gptkbp:clinical_use |
prevent seasonal flu
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
consult healthcare provider before use |
| gptkbp:country_of_origin |
gptkb:Belgium
|
| gptkbp:dosage_form |
suspension
|
| gptkbp:formulation |
gptkb:liquid
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fluarix
|
| gptkbp:ingredients |
inactivated influenza virus
|
| gptkbp:is_vulnerable_to |
global
varies by location varies by season refrigerated ongoing improvements quadrivalent high-risk populations updated annually introduced in 2005 available in pharmacies adverse event reporting system depends on match with circulating strains trained healthcare provider CDC recommends for all ages based on previous strains before flu season reduces flu-related hospitalizations |
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:market |
ongoing
|
| gptkbp:packaging |
single-dose vials
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
generally well-tolerated
|
| gptkbp:service_frequency |
gptkb:annually
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever pain at injection site anaphylaxis (rare) |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:target_audience |
adults and children
|
| gptkbp:type |
inactivated influenza vaccine
|
| gptkbp:used_for |
influenza prevention
|
| gptkbp:vaccine_awareness_campaigns |
conducted by health organizations
|
| gptkbp:vaccine_community_impact |
promotes herd immunity
|
| gptkbp:vaccine_guidelines |
follow CDC recommendations
|
| gptkbp:vaccine_insurance_coverage |
often covered by insurance
|
| gptkbp:vaccine_patient_information |
provided with each dose
|
| gptkbp:vaccine_updates |
annual reformulation
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:bfsLayer |
5
|